Immunosuppressive regulatory cells in cancer immunotherapy: restrain or modulate?
Authors:
- 30 May 2024
- journal article
- review article
- Published by Springer Nature in Human Cell
- Vol. 37 (4) , 931-943
Abstract
Immunosuppressive regulatory cells (IRCs) play important roles in negatively regulating immune response, and are mainly divided into myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). Large numbers of preclinical and clinical studies have shown that inhibition or reduction of IRCs could effectively elevate antitumor immune responses. However, several studies also reported that excessive inhibition of IRCs function is one of the main reasons causing the side effects of cancer immunotherapy. Therefore, the reasonable regulation of IRCs is crucial for improving the safety and efficiency of cancer immunotherapy. In this review, we summarised the recent research advances in the cancer immunotherapy by regulating the proportion of IRCs, and discussed the roles of IRCs in regulating tumour immune evasion and drug resistance to immunotherapies. Furthermore, we also discussed how to balance the potential opportunities and challenges of using IRCs to improve the safety of cancer immunotherapies.Keywords
Funding Information
- High Performance Computing Platform of Jiangsu University (18JDG028, 21JDG061)
- National Natural Science Foundation of China (82202542)
This publication has 127 references indexed in Scilit:
- The effects of TNF‐α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancerInternational Journal of Cancer, 2021
- Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected MelanomaJAMA Oncology, 2021
- Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primatesCancer Immunology, Immunotherapy, 2019
- How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutionsCancer Immunology, Immunotherapy, 2018
- Aging of the immune system: Focus on inflammation and vaccinationEuropean Journal of Immunology, 2016
- Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patientsCancer Immunology, Immunotherapy, 2015
- Lenalidomide‐based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patientsAmerican Journal of Hematology, 2014
- Extracellular adenosine metabolism in immune cells in melanomaCancer Immunology, Immunotherapy, 2014
- Tumor‐induced myeloid‐derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+T‐cell activation eventsEuropean Journal of Immunology, 2013
- Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor #Hepatology, 2009